Document is current
Any future updates will be listed below
-
Authors
Warady, Bradley A. https://orcid.org/0000-0003-1812-6587
Heeg, Simone https://orcid.org/0000-0001-7503-1213
Farjat, Alfredo E.
Knapp, Rachel https://orcid.org/0000-0002-7685-1333
Saydam, Siir Su https://orcid.org/0000-0002-0554-8361
Vowinkel, Alexander
Gay, Alain
Potts, James
Scalise, Andrea https://orcid.org/0000-0002-9367-5773
Atanackovic, Gordana
van Boemmel-Wegmann, Sascha https://orcid.org/0000-0002-6518-7254
-
Funding
Funding for this research was provided by:
Pharmaceuticals Bayer
- License Information
-
More Information
Article History
Received: 24 March 2026
Revised: 15 May 2026
Accepted: 17 June 2026
First Online: 6 July 2026
Declarations
:
: Use of Optum® EHR was reviewed by the New England Institutional Review Board and was determined to be exempt because the project did not involve human subject research.
: BAW is a member of the Steering Committee of the FIONA trial and has received honoraria from Bayer. SH, AEF, RK, JP, AS, and GA are employees of Bayer. SSS, AV, AG, and SvBW were employees of Bayer at the time of study conduct.
